EMA announces mRNA update to seasonal flu vaccine guidance

The European Medicines Agency says its 2026/2027 recommendations now include mRNA influenza vaccines, alongside an update to its vaccine standardisation annex.

Numbers in brackets link to the sources listed below.

The European Medicines Agency said it updated its 2026/2027 seasonal influenza vaccine composition recommendations on 17 November 2026 to include mRNA vaccines[1European Medicines AgencyEU recommendations for 2026/2027 seasonal flu vaccine compositionOpen sourceSources [1]]. The agency also reported changes to Annex I, which covers reagents used in vaccine standardisation[1European Medicines AgencyEU recommendations for 2026/2027 seasonal flu vaccine compositionOpen sourceSources [1]].

EMA says the recommendations specify which influenza strains or sequences manufacturers should use in vaccines intended to prevent seasonal flu from autumn 2026[1European Medicines AgencyEU recommendations for 2026/2027 seasonal flu vaccine compositionOpen sourceSources [1]]. It directs readers to the latest document under its page’s ‘Related documents’ section for the additional strains and sequences[1European Medicines AgencyEU recommendations for 2026/2027 seasonal flu vaccine compositionOpen sourceSources [1]].

According to the U.S. National Library of Medicine, mRNA stands for messenger RNA; in these vaccines, it provides instructions that cells use to produce a germ’s protein or a fragment of it[3U.S. National Library of MedicineWhat are mRNA vaccines and how do they work?Open sourceSources [3]]. The resulting protein prompts an immune response, including antibody production, and cells subsequently break down the mRNA[3U.S. National Library of MedicineWhat are mRNA vaccines and how do they work?Open sourceSources [3]].

EMA’s update history lists earlier additions on 7 May 2026 concerning strains for egg-based and live-attenuated influenza vaccines[1European Medicines AgencyEU recommendations for 2026/2027 seasonal flu vaccine compositionOpen sourceSources [1]]. The agency says a further update on 26 May 2026 covered an A/H3N2 virus suitable for cell-based seasonal vaccines and a B-lineage virus suitable for live-attenuated seasonal vaccines[1European Medicines AgencyEU recommendations for 2026/2027 seasonal flu vaccine compositionOpen sourceSources [1]].

Sources

  1. 1
    EU recommendations for 2026/2027 seasonal flu vaccine composition

    PrimaryEuropean Medicines AgencyAccessed

  2. 2
  3. 3
    What are mRNA vaccines and how do they work?

    IndependentU.S. National Library of MedicineAccessed

ITANU’s newsroom system produced this article with AI and checked it against the sources listed above. How we work

ITANU Magazine

AI, computing and science news